Shin Poong Pharm.Co.Ltd. (019170) - Total Assets
Based on the latest financial reports, Shin Poong Pharm.Co.Ltd. (019170) holds total assets worth ₩341.59 Billion KRW (≈ $231.49 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Shin Poong Pharm.Co.Ltd. (019170) net assets for net asset value and shareholders' equity analysis.
Shin Poong Pharm.Co.Ltd. - Total Assets Trend (2003–2024)
This chart illustrates how Shin Poong Pharm.Co.Ltd.'s total assets have evolved over time, based on quarterly financial data.
Shin Poong Pharm.Co.Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Shin Poong Pharm.Co.Ltd.'s total assets of ₩341.59 Billion consist of 55.3% current assets and 44.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 12.3% |
| Accounts Receivable | ₩70.16 Billion | 20.5% |
| Inventory | ₩55.38 Billion | 16.2% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩5.01 Billion | 1.5% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how Shin Poong Pharm.Co.Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Shin Poong Pharm.Co.Ltd. market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shin Poong Pharm.Co.Ltd.'s current assets represent 55.3% of total assets in 2024, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 12.3% of total assets in 2024, up from 0.9% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 20.5% of total assets.
Shin Poong Pharm.Co.Ltd. Competitors by Total Assets
Key competitors of Shin Poong Pharm.Co.Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Shin Poong Pharm.Co.Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.74 | 2.92 | 3.99 |
| Quick Ratio | 1.90 | 2.10 | 3.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩123.55 Billion | ₩127.35 Billion | ₩249.47 Billion |
Shin Poong Pharm.Co.Ltd. - Advanced Valuation Insights
This section examines the relationship between Shin Poong Pharm.Co.Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.14 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -2.3% |
| Total Assets | ₩342.09 Billion |
| Market Capitalization | $390.33 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shin Poong Pharm.Co.Ltd.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Shin Poong Pharm.Co.Ltd.'s assets decreased by 2.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Shin Poong Pharm.Co.Ltd. (2003–2024)
The table below shows the annual total assets of Shin Poong Pharm.Co.Ltd. from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩342.09 Billion ≈ $231.83 Million |
-2.28% |
| 2023-12-31 | ₩350.08 Billion ≈ $237.25 Million |
-3.17% |
| 2022-12-31 | ₩361.54 Billion ≈ $245.01 Million |
-7.91% |
| 2021-12-31 | ₩392.58 Billion ≈ $266.05 Million |
-19.41% |
| 2020-12-31 | ₩487.15 Billion ≈ $330.13 Million |
+28.16% |
| 2019-12-31 | ₩380.11 Billion ≈ $257.60 Million |
-0.22% |
| 2018-12-31 | ₩380.95 Billion ≈ $258.17 Million |
-1.21% |
| 2017-12-31 | ₩385.61 Billion ≈ $261.32 Million |
-7.41% |
| 2016-12-31 | ₩416.49 Billion ≈ $282.25 Million |
+1.40% |
| 2015-12-31 | ₩410.73 Billion ≈ $278.35 Million |
+0.35% |
| 2014-12-31 | ₩409.30 Billion ≈ $277.37 Million |
+2.75% |
| 2013-12-31 | ₩398.35 Billion ≈ $269.96 Million |
+4.92% |
| 2012-12-31 | ₩379.68 Billion ≈ $257.30 Million |
+0.31% |
| 2011-12-31 | ₩378.50 Billion ≈ $256.50 Million |
+17.94% |
| 2010-12-31 | ₩320.93 Billion ≈ $217.49 Million |
+3.48% |
| 2009-12-31 | ₩310.15 Billion ≈ $210.19 Million |
+15.47% |
| 2008-12-31 | ₩268.61 Billion ≈ $182.03 Million |
+23.69% |
| 2007-12-31 | ₩217.16 Billion ≈ $147.17 Million |
+8.00% |
| 2006-12-31 | ₩201.07 Billion ≈ $136.26 Million |
+5.78% |
| 2005-12-31 | ₩190.07 Billion ≈ $128.81 Million |
+8.75% |
| 2004-12-31 | ₩174.77 Billion ≈ $118.44 Million |
+5.16% |
| 2003-12-31 | ₩166.19 Billion ≈ $112.63 Million |
-- |
About Shin Poong Pharm.Co.Ltd.
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more